Epigenetic therapy for ovarian cancer: promise and progress

Epigenetic therapy for ovarian cancer: promise and progress

Abstract Ovarian cancer is the deadliest gynecologic malignancy, with a 5-year survival rate of approximately 47%, a number that has remained constant over the past two decades. Early diagnosis improves survival, but unfortunately only 15% of ovarian cancers are diagnosed at an early or localized st...

Full description

Bibliographic Details
Main Authors: Sara Moufarrij, Monica Dandapani, Elisa Arthofer, Stephanie Gomez, Aneil Srivastava, Micael Lopez-Acevedo, Alejandro Villagra, Katherine B. Chiappinelli
Format: Article
Language:English
Published: BMC 2019-01-01
Series:Clinical Epigenetics
Subjects:
Ovarian cancer
Epigenetics
DNA methylation
Histone modifications
DNMT inhibitors
HDAC inhibitors
Online Access:http://link.springer.com/article/10.1186/s13148-018-0602-0

Internet

http://link.springer.com/article/10.1186/s13148-018-0602-0

Similar Items